Definium Therapeutics (DFTX) Competitors

Definium Therapeutics logo
$28.47 -0.91 (-3.10%)
As of 11:15 AM Eastern

DFTX vs. NBIX, JAZZ, ELAN, RDY, and CORT

Should you buy Definium Therapeutics stock or one of its competitors? Definium Therapeutics's main competitors and comparable companies include Neurocrine Biosciences (NBIX), Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), and Corcept Therapeutics (CORT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Definium Therapeutics compare to Neurocrine Biosciences?

Definium Therapeutics (NASDAQ:DFTX) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

In the previous week, Definium Therapeutics had 9 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 14 mentions for Definium Therapeutics and 5 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.01 beat Definium Therapeutics' score of 0.60 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Neurocrine Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Neurocrine Biosciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A
Neurocrine Biosciences$2.86B5.87$478.60M$6.7424.62

Neurocrine Biosciences has a net margin of 18.98% compared to Definium Therapeutics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 23.39% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -53.23% -43.90%
Neurocrine Biosciences 18.98%23.39%16.22%

Definium Therapeutics currently has a consensus price target of $66.29, indicating a potential upside of 125.64%. Neurocrine Biosciences has a consensus price target of $202.59, indicating a potential upside of 22.10%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Definium Therapeutics is more favorable than Neurocrine Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95
Neurocrine Biosciences
0 Sell rating(s)
4 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.88

Summary

Neurocrine Biosciences beats Definium Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Definium Therapeutics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Jazz Pharmaceuticals has a net margin of 4.37% compared to Definium Therapeutics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 16.88% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals4.37% 16.88% 6.46%
Definium Therapeutics N/A -53.23%-43.90%

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Definium Therapeutics had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 14 mentions for Definium Therapeutics and 9 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.82 beat Definium Therapeutics' score of 0.60 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Definium Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Jazz Pharmaceuticals presently has a consensus price target of $294.25, indicating a potential upside of 22.24%. Definium Therapeutics has a consensus price target of $66.29, indicating a potential upside of 125.64%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Jazz Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.95
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95

Definium Therapeutics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Definium Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$4.27B3.62-$356.15M$2.9481.87
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A

Jazz Pharmaceuticals has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Summary

Jazz Pharmaceuticals beats Definium Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Elanco Animal Health?

Definium Therapeutics (NASDAQ:DFTX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Definium Therapeutics presently has a consensus price target of $66.29, indicating a potential upside of 125.64%. Elanco Animal Health has a consensus price target of $29.75, indicating a potential upside of 14.98%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Elanco Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

Definium Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A
Elanco Animal Health$4.72B2.74-$232M-$0.30N/A

Definium Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market.

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Definium Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -2.86%. Elanco Animal Health's return on equity of 8.80% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -53.23% -43.90%
Elanco Animal Health -2.86%8.80%4.32%

In the previous week, Definium Therapeutics had 9 more articles in the media than Elanco Animal Health. MarketBeat recorded 14 mentions for Definium Therapeutics and 5 mentions for Elanco Animal Health. Definium Therapeutics' average media sentiment score of 0.60 beat Elanco Animal Health's score of 0.55 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Elanco Animal Health
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Definium Therapeutics beats Elanco Animal Health on 10 of the 15 factors compared between the two stocks.

How does Definium Therapeutics compare to Dr. Reddy's Laboratories?

Definium Therapeutics (NASDAQ:DFTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

In the previous week, Definium Therapeutics had 12 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 14 mentions for Definium Therapeutics and 2 mentions for Dr. Reddy's Laboratories. Definium Therapeutics' average media sentiment score of 0.60 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Definium Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Definium Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Dr. Reddy's Laboratories
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Dr. Reddy's Laboratories has a net margin of 8.56% compared to Definium Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 7.91% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Definium TherapeuticsN/A -53.23% -43.90%
Dr. Reddy's Laboratories 8.56%7.91%5.29%

Definium Therapeutics currently has a consensus target price of $66.29, indicating a potential upside of 125.64%. Dr. Reddy's Laboratories has a consensus target price of $492.90, indicating a potential upside of 3,229.28%. Given Dr. Reddy's Laboratories' higher probable upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Definium Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95
Dr. Reddy's Laboratories
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A
Dr. Reddy's Laboratories$3.58B3.45$456M$0.3740.01

Summary

Definium Therapeutics and Dr. Reddy's Laboratories tied by winning 8 of the 16 factors compared between the two stocks.

How does Definium Therapeutics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

In the previous week, Definium Therapeutics had 8 more articles in the media than Corcept Therapeutics. MarketBeat recorded 14 mentions for Definium Therapeutics and 6 mentions for Corcept Therapeutics. Definium Therapeutics' average media sentiment score of 0.60 beat Corcept Therapeutics' score of 0.59 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Definium Therapeutics
4 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Corcept Therapeutics has a net margin of 16.53% compared to Definium Therapeutics' net margin of 0.00%. Corcept Therapeutics' return on equity of 22.56% beat Definium Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics16.53% 22.56% 17.83%
Definium Therapeutics N/A -53.23%-43.90%

Corcept Therapeutics has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M10.07$99.65M$1.2755.17
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A

Corcept Therapeutics presently has a consensus price target of $139.50, indicating a potential upside of 99.09%. Definium Therapeutics has a consensus price target of $66.29, indicating a potential upside of 125.64%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Definium Therapeutics is more favorable than Corcept Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95

Corcept Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the broader market.

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 2.4% of Definium Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Corcept Therapeutics beats Definium Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Definium Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DFTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DFTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DFTX vs. The Competition

MetricDefinium TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.90B$13.42B$7.65B$11.69B
Dividend YieldN/A2.58%2.47%4.46%
P/E Ratio-9.1528.7833.9329.91
Price / SalesN/A7.298.455.70
Price / CashN/A15.6321.0121.90
Price / Book4.035.444.473.74
Net Income-$183.79M$2.88B$3.51B$393.98M
7 Day Performance-17.41%-4.59%-5.96%-5.71%
1 Month Performance-11.31%-4.27%-4.39%-7.03%
1 Year Performance149.52%-7.06%-1.32%-7.26%

Definium Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DFTX
Definium Therapeutics
3.1297 of 5 stars
$28.47
-3.1%
$66.29
+132.9%
+159.1%$3.90BN/AN/A40
NBIX
Neurocrine Biosciences
4.8893 of 5 stars
$165.31
-1.2%
$202.59
+22.6%
+15.6%$17.15B$2.86B21.232,000
JAZZ
Jazz Pharmaceuticals
4.5199 of 5 stars
$239.77
-0.7%
$294.25
+22.7%
+41.5%$15.43B$4.27B21.312,890
ELAN
Elanco Animal Health
3.1271 of 5 stars
$26.48
-1.1%
$29.75
+12.4%
+20.8%$13.25B$4.72BN/A9,400
RDY
Dr. Reddy's Laboratories
3.3331 of 5 stars
$14.71
-0.2%
$492.90
+3,251.9%
+5.9%$12.29B$3.58B39.7427,527

Related Companies and Tools


This page (NASDAQ:DFTX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners